Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae.

Smith, Kenneth P, and James E Kirby. 2016. “Evaluation of Apramycin Activity Against Carbapenem-Resistant and -Susceptible Strains of Enterobacteriaceae.”. Diagnostic Microbiology and Infectious Disease 86 (4): 439-41.

Abstract

We evaluated activity of apramycin, a non-ototoxic/non-nephrotoxic aminocyclitol against 141 clinical Enterobacteriaceae isolates, 51% of which were non-susceptible to carbapenems (CRE). Among CRE, 70.8% were apramycin susceptible, which compared favorably to aminoglycosides in current clinical use. Our data suggest that apramycin deserves further investigation as a repurposed, anti-CRE therapeutic.

Last updated on 08/16/2024
PubMed